

108. Zimmermann T, Laufen H, Yeates RA. Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam [abstract no. 777]. 7th European Congress of Clinical Microbiology and Infectious Diseases; 1995 Mar 26-30; Vienna, 151
109. Ljutić D, Rumboldt Z. Possible interaction between azithromycin and cyclosporin: a case report. *Nephron* 1995 May; 70: 130
110. Association of the British Pharmaceutical Industry. Zithromax. In: Walker G, editor. ABPI Data Sheet Compendium 1994-95. London: Datapharm Publications Ltd., 1994: 1285-6
111. Foulds G, Luke DR, Teng R, et al. Food does not affect the bioavailability of azithromycin tablets, sachet, or suspension. *J Antimicrob Chemother*. In press
112. Schentag JJ. Antibiotic treatment of acute otitis media in children: dosing considerations. *Pediatr Infect Dis J* 1995; 14 (4): S30-33
113. Ball P, Tillotson G, Wilson R. Chemotherapy for chronic bronchitis: controversies. *Presse Med* 1995 Jan 21; 24: 189-94
114. Place in therapy of the newer macrolides: clarithromycin and azithromycin. *Drug Ther Perspect* 1993 Jan 25; 1 1: 5-7
115. Cook PJ, Honeybourne D. Clinical aspects of *Chlamydia pneumoniae* infection. *Presse Med* 1995 Feb 4; 24: 278-82
116. Grayston JT. Infections caused by *Chlamydia pneumoniae* strain TWAR. *Clin Infect Dis* 1992 Nov; 15: 757-63
117. Feldman JA, DeTullio PL. Medication noncompliance: an issue to consider in the drug selection process. *Hosp Formul* 1994 Mar; 29: 204-11
118. Pfizer on Zithromax cost. *Scrip Mag* 1995 Jul 4 (2039): 23
119. American Thoracic Society. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. *Am Rev Respir Dis* 1993; 148: 1418-26
120. Eron JJJ, Burkle W, Cohen MS. Managing pneumonia: defining the role of the new macrolide antibiotics. *Hosp Formul* 1994 Feb; 29: 122-36

Correspondence: Christopher J. Dunn, Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand.

## Errata

- Vol. 50, No. 4, page 670:** In table III, the references listed in the first column should read: Barchiesi et al.<sup>[99]</sup>, Laine et al.<sup>[111]</sup>, Hernández-Sampelayo et al.<sup>[105]</sup>, Frechette et al.<sup>[112]</sup>, Graybill et al.<sup>[113]</sup>, Pons et al.<sup>[107]</sup>, Pons et al.<sup>[114]</sup>, Brockmeyer et al.<sup>[106]</sup>, Larsen et al.<sup>[115]</sup>, Saag et al.<sup>[116]</sup>.
- page 673:** In table IV, the references listed in the first column should read: Bozzette et al.<sup>[129]</sup>, Powderly et al.<sup>[130]</sup>, Saag et al.<sup>[131]</sup>, Powderly et al.<sup>[121]</sup>, Nightingale<sup>[132]</sup>.
- page 676:** In table V, the Samonis reference in the first column should read: Samonis et al.<sup>[151]</sup>.
- page 678:** In table VI, the references listed in the first column should read: Bodey et al.<sup>[153]</sup>, Menichetti et al.<sup>[154]</sup>, Meunier et al.<sup>[155]</sup>, Philpott-Howard et al.<sup>[156]</sup>, Ninane et al.<sup>[157]</sup>, Ellis et al.<sup>[158]</sup>.
- page 681:** In table VII, the table heading should read: '... in the US<sup>[165]</sup> and the UK<sup>[197]</sup>'.

[Goa KL, Barradell LB. Fluconazole: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. *Drugs* 1995 Oct; 50 (4): 658-690]

**Vol. 51, No. 1, page 9:** Table I was inadvertently omitted from the article and should read as follows:

**Table I.** Antipsychotic drug displacement at dopamine D<sub>2</sub> and D<sub>4</sub> receptors

	Ki values (nmol/L)		References
	D <sub>2</sub>	D <sub>4</sub>	
Chlorpromazine	1.3-2.0	7.9-35	16,17,19
Clozapine	55-229	9-55	16-19
Haloperidol	0.4-1.0	2.0-5.2	16-19
Loxapine	9.9	29	17
Melperone	182	139	17
Olanzapine	11-45	27	16,20
Sulpiride	17	569-1005	16,19
Thioridazine	2.8-4.9	14-23	17,19
Trifluoperazine	1.1	32	17

[Reynolds GP. The importance of dopamine D<sub>4</sub> receptors in the action and development of antipsychotic agents. *Drugs* 1996 Jan; 51 (1): 7-11]